- Open Access
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Arthritis Research & Therapyvolume 18, Article number: 236 (2016)
The original article was published in Arthritis Research & Therapy 2016 18:214
Unfortunately, after publication of this article , it was noticed that the name of Jeffrey N. Miner was captured incorrectly during the production process. The middle initial ‘N’ was missing from the list. The corrected author list can be seen above and the original article has been updated to correct this error.
Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L, Yeh L-T, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214. doi:10.1186/s13075-016-1107-x.
The online version of the original article can be found under doi:10.1186/s13075-016-1107-x.